Clinical trial · Observational
Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation
Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation: FACT STUDY
NCT01729676CI-TRIAL-00015116FACTcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
French epidemiological data have shown a heterogeneous distribution of the risk of mortality from prostate cancer according to region. The main objective is to describe the distribution of prostate cancer stages when first line hormonal therapy is introduced (overall and by region).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Degarelix or GnRH agonist | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Group A
- description
- Degarelix or gonadotrophin releasing hormone (GnRH) agonist for treatment of prostate cancer according to physicians current practice
- interventionNames
- Drug: Degarelix or GnRH agonist
Primary outcomes (1)
- measure
- Estimated percentage of different prostate cancer stages (overall and by region)
- timeFrame
- During a single consultation when first-line prostate cancer hormone therapy is started
- description
- The stages of prostate cancer are classified as locally advanced, metastatic and biological recurrence.
Secondary outcomes (2)
- measure
- The characteristics of the patients with prostate cancer by region
- timeFrame
- During a single consultation when first-line prostate cancer hormone therapy is started
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically demonstrated prostatic adenocarcinoma. * Patients never previously treated with hormonal therapy for prostate cancer. * Patients eligible for hormonal therapy after initial consultation (alone or in combination with curative treatment). * Patients agreeing to the collection of personal health data for the purposes of the study. * Patients with locally advanced or metastatic prostatic cancer tumours or a biological recurrence after curative treatment. Exclusion Criteria: * Patients participating in a clinical study involving prostate cancer at the time of inclusion in the investigation. * Patients having received or currently receiving hormonal treatment for prostate cancer (surgical castration or other hormonal manipulation, including GnRH receptor antagonists, antiandrogens, oestrogens, 5 alpha reductase inhibitors).
References
Publications (0)
Data not yet available
No reference posted for this study.